Radiomics,aptamers and nanobodies: New insights in cancer diagnostics and imaging

Abstract

At present, cancer is a major health issue and the second leading cause of mortality worldwide. Researchers have been working hard on investigating not only improved therapeutics but also on early detection methods, both critical to increasing treatment efficacy and developing methods for disease prevention. Diagnosis of cancers at an early stage can promote timely medical intervention and effective treatment and will result in inhibiting tumor growth and development. Several advances have been made in the diagnostics and imagining technologies for early tumor detection and deciding an effective therapy these include radiomics, nanobodies, and aptamers. Here in this review, we summarize the main applications of radiomics, aptamers, and the use of nanobody-based probes for molecular imaging applications in diagnosis, treatment planning, and evaluations in the field of oncology to develop quantitative and personalized medicine. The preclinical data reported to date are quite promising, and it is predicted that nanobody-based molecular imaging agents will play an important role in the diagnosis and management of different cancer types in near future.

Keywords

Radiomics medical images PET SPECT nanobody aptamers probes antibody cancer

1. Introduction

Cancer is emerging as a global health problem throughout the world and is the second leading cause of death worldwide exceeded only by cardiovascular diseases [1]. Tumors develop due to mutations in genes, or due to activation of oncogenes resulting in loss of cell cycle control system, leading to uncontrolled mitosis of cells [2]. At present, radiotherapy, chemotherapy, and immunotherapy are the most common methods used for the treatment of cancer and have significantly improved the prognosis of cancer patients [3, 4, 5]. However, the treatment of malignant tumors in particular late-stage tumors is difficult as the seeding of tumor cells at distant metastatic sites. Once metastasis has occurred, the conventional treatment methods fail to inhibit tumor growth, leading to decreased prognosis [6]. In most cases of tumor development, tumors go undetected at early stages, therefore advances in the detection and diagnosis of early-stage tumors will significantly help in improving patient survival [7]. Tumor detection methods have significantly advanced and molecular diagnosis has become an essential part of cancer prognosis. The evolution of molecular diagnostics has driven several technological developments, which have a clinical relevance of incorporating the novel investigations in diagnostic practices [7]. Presently molecular characterization of cancer has become a very fundamental consequence in cancer treatment both for prognostic testing as well as classification of different tumors [8].

The development of robust, high-quality diagnostic tests for technical as well as clinical support will significantly improve the overall survival (OS) and relapse-free survival (RFS) of cancer patients [9]. Several advances in the diagnostics methods including radiomics, nanobody-based diagnosis, and aptamers in diagnosis and detection of tumors show promising results. Radiomics equipped with computational power, machine learning, as well as artificial intelligence technology have been found to significantly quantify diagnosis and prognostic biomarkers and proving ancillary guidance in the field of oncology and are proving promising in developing quantitative and personalized medicine [10].

Besides, recent advances point in radiomics point that the concept of encryption of different tumors and their microenvironment based on phenotypes will significantly improve early detection and diagnosis [10]. Likewise, aptamers, short non-coding, single-stranded oligonucleotides (RNA or DNA) show promising results in the detection and diagnosis of tumors [11]. Antibodies are currently widely used in the detection and diagnostics of tumors, however high immunogenicity, low stability, and product cost limit the use of antibodies [12]. In contrast, aptamers possess a high ability to bind to specific targets with high affinity, with low immunogenicity, production costs, and high stability [11]. Also, diverse aptamer-nanobody conjugates have been developed and widely investigated for diagnostics and targeted therapy in different cancers and point to promising outcomes [13].

Nanobodies are heavy chain only antibodies (HcAbs) and were serendipitously discovered in camelids [14]. The HcAbs comprises of just two heavy chains, with a single variable domain and possess significantly low molecular weight compared to normal antibodies [15]. These nanoscale VHHs were defined by the name “nanobodies” and could retain full antigen-binding potential upon isolation, establishing them as the smallest, naturally-derived antigen-binding fragment [16]. Several studies report that nanobodies due to their high specificity can be utilized in specific diagnostics of tumors and as molecular imaging probes [15]. Also, the high stability of nanobodies in harsh conditions such as high temperature, pH, or ionic strength further points towards their application [17]. At present several nanobodies are in clinical trials for the detection and imaging of diverse tumors [15].

Here in this review, we will shed light on the recent advances in radiomics, aptamers, and nanobodies in the detection, diagnosis, and imaging of tumors.

2. Radiomics in tumor diagnosis and prognosis

The concept of radiomics was first proposed in 2012 and has subsequently attracted the responsiveness of researchers all over the world [18]. It involves the extraction of quantitative, and subvisual features of radiological images to develop mineable databases [19]. Interestingly, the features of the radiomics have been demonstrated to correlate with disease pathologies in particular tumors [10]. Thus, a lot of interest has been taken to utilize radiomics in tumor screening to increase sensitivity and specificity. In addition to diagnosis, radiomics can also be utilized to predict the outcome of therapies in cancer patients [20]. Radiomics typically initiates using data acquisition, where it depends on a huge tome of medical images, thus conforming clinical data in revealing the association that exists between them Fig. 1 [21]. It was first of all proposed using CT images and then in the analysis of MR images, and later PET images were also utilizing the related strategy [21, 22, 23, 105]. Several studies have been done demonstrating the value of radiomics in improving the diagnosis and treatment of cancer [20]. In brief, the aim of radiomics is to translate the tumor-inherited phenotypes using noninvasive imaging [24]. Presently radiomics analysis involves images that are mostly digital imaging which includes; CT, magnetic resonance imaging (MRI), and positron emission tomography (PET) [25]. The innovations in high-throughput computing and machine learning algorithms have led to the advent of the radiomics concept which refers to a collective categorization as well as quantification of biological information example; metabolomics, proteomics and genomics. In simple radiomics refers to a programmed intellection of either 2-dimentional or 3-dimentional medical images and their subsequent application in data mining and analysis of techniques describing shape, histogram as well as texture features extracted from several imaging modalities such as; CT, MRI or FDG-PET (18-fludeoxyglucose positron emission tomography) [26].

Figure 1.

Work flow of radiomic approach. (A) Workflow of extracting radiomic features: (I) A lung tumor is scanned in multiple slices. (II) Next, the tumor is delineated in every slice and validated by an experienced physician. This allows creation of a 3D representation of the tumor outlining phenotypic differences of tumors. (III) Radiomic features are extracted from this 3D mask, and (IV) integrated with genomic and clinical data. (B) Representative examples of lung cancer tumors. Visual and nonvisual differences in tumor shape and texture between patients can be objectively defined by radiomics features, such as entropy of voxel intensity values.

Ever since the radiomics has come into the medical field, several studies have been done improving the diagnosis and treatment of several types of cancers including; lung cancer, head-and-neck cancer, liver cancer, prostate cancer, gastric cancer, colorectal cancer, brain cancer, and breast cancer [27]. The standard brain imaging although grades tumors, however, improve was needed for high precision [28]. Bai et al. first exploited the diffusion kurtosis MRI, categorizing different gliomas, and reported promising results in gliomas grading [28]. Besides, radiomics attracted the attention for predicting molecular subtyping of brain tumors [29]. The precision diagnosis of gene expression patterns utilizing could pave and promote targeted therapies thereby augmenting prognosis. Additionally, in the prediction of molecular subtyping of brain tumors, mutations in Isocitrate dehydrogenase (IDH), O6-methylguanine-DNA methyltransferase (MGMT), 1p/19q co-deletion, EGFR expression level, Ki-67 expression level, p53 status, and ATRX have been the main focus [27]. Besides, utilizing radiomic analysis in multi-parametric MRI helped in the prediction of molecular characteristics. More importantly, imaging phenotypes were shown to be associated with molecular pathway activities that may determine the type of targeted therapy [30].

Moreover, in glioblastoma patients, identifying the imaging phenotypes helped in the prediction of treatment evaluation and prognosis in patients. For example; utilizing radiomics different responses were predicted for the bevacizumab treated recurrent glioblastoma patients [29, 31]. Besides, studies demonstrate that characteristics detected by MRI and PET images predict the survival of glioma patients [32].

Radiomics has been widely explored in head and neck cancer [25]. An MRI-based signature that can be used in radiomics was built by Ren et al. aiding in predicting the tumor stage in head and neck cancer. The study reported that MRI-based radiomic signature significantly decimated different stages of tumor [33]. Additionally, a CT radiomic signature reported by Leijenaar et al. was found to predict the status of HPV (p16) in oropharyngeal squamous cell carcinoma [34].

Breast cancer is one of the most common malignancy among women and the leading cause of death [35, 36]. The high heterogeneity of breast tumors demands precise diagnosis and early prediction of response to the treatment. Presently, radiomics, in combination with data from multi-modality imaging and clinical information, is now used widely in breast cancer research. Breast cancer is detected by several imaging techniques, including the US, PET/CT, mammography, and MRI [37, 38, 39, 40, 41]. Consequently, the imaging data can be utilized in radiomics to predict tumor heterogeneity, diagnosis, and prognosis [27]. Many studies have employed radiomics in predicting subtypes of breast cancer or the expression of hormone receptors/markers etc. Also, Antropova et al., proposed the combination of US, MRI, and mammography data fusion to improve diagnosis and detection of breast tumors [37]. Moreover, in breast cancer radiomics was employed to study the response of patients to therapies [42]. Using a pretreatment MRI scan, Chan et al. predicted the treatment failure in early breast cancer patients [42]. Also, Braman et al. reported that intra- and peri-tumoral features of DCE-MRI could help in pretreatment prediction of pathological complete response (pCR) [43].

Additionally, radiomics has been utilized in diagnosis, treatment evaluation, and prognosis in lung cancer [44, 45]. Lung cancer at present is the most lethal type of cancer and its incidence continues to rise worldwide due to smoking, pollution, and other factors [1]. Using LIDC-IDRI datasets, Kumar et al. was able to classify the malignant and benign liver tumors and achieved a sensitivity of 79.06% and a specificity of 76.11% [46]. A deep learning model based on CT image data predicted better results for malignant lung nodule in contrast to previous methods [47]. Evaluation of response to treatment is important in lung cancer due to its significance in the treatment decision. Studies revealed that radiomic signatures could aid in predicting the recurrence after Stereotactic Ablative Radiation Therapy (SART) in Lung Cancer [48, 49]. Also utilizing delta-radiomic features predicted the outcomes in Stage III NSCLC patients during the radiation therapy [50]. Their results suggest the change of radiomic features due to radiation therapy would be indicators of tumor response. Also, Coroller et al. reported that analyzing the pretreated CT radiomic features could aid in predicting the pCR in patients with advanced NSCLC after neoadjuvant chemoradiation [51]. Furthermore, Song et al. concluded that radiomic signatures based on CT are associated with prognosis and thus could help to predict progression-free survival after therapy with tyrosine kinase inhibitors [52]. In addition to therapeutic outcomes, many radiomic studies have focused on prognosis. For example, Aerts et al. demonstrated that the clusters of radiomic features correlated with the prognosis of lung cancer [53]. Also, the relationship between CT radiomic characteristics and overall survival in patients with also reported in NSCLC [54]. Furthermore, Balagurunathan et al. analyzed the reproducibility and prognosis of quantitative radiomic features from CT images, and many features were associated with the prognosis of lung cancer [55].

Together these results paint the picture of applications of radiomics in oncology. However, radiomics is still a naive and developing field and several advances on reproducibility and interpretation are needed.

3. Nanobodies in cancer diagnostics and imaging

Vaccines and monoclonal antibodies have been explored at length for diagnostics and as therapeutics in many diseases including cancer [56, 57, 58]. Monoclonal antibodies possess a large size that limits their function in solid tumors, in large part due to unique characteristics of tumor microenvironment such as high pressure of tumor interstitial fluid [59]. Smaller formats of antibodies have been developed to tackle such limits, which include antigen-binding fragments, single-chain variable fragments, single variable domain of camelid antibody (so-called nanobody (Nb) or VHH) [60, 61]. Three decades ago, it was serendipitously discovered that camelids (dromedaries, camels, llamas, alpacas, guanacos, and vicuñas) possess unique efficient heavy-chain-only antibodies [62]. These heavy chain-only antibodies (HCAbs) display alike affinity to their cognate antigen, even though these have only one single variable domain (VHH) for antigen recognition [15]. Studies have revealed that these autonomous VHH are the smallest natural intact antigen-binding fragment and retain their full antigen-binding potential [63, 64]. Nanobodies have a very small size (15 kDa) and dimensions in the nanometer range ( $\sim$ 2.5 nm in diameter and $\sim$ 4 nm in height) and have received immense interest in diagnostics and therapeutics in tumor biology. Furthermore, these single-domain antibodies are highly stable, and due to the small size show large tissue permeability demonstrating advantageous physicochemical and pharmacological features [14]. Nbs offers multiple applications in therapeutics including tumor immunotherapy, fundamental research, and diagnostics [65, 66].

Figure 2.

Therapeutic and diagnostic potential of nanobodies in cancer. Nanobodies due their high size, low immunogenicity, and very small size demonstrate potential in treatment as well as in diagnostics and imaging tumors.

4. Therapeutic and diagnostic potential of nanobodies in cancer

Nanobodies due their high size, low immunogenicity, and very small size demonstrate potential in treatment as well as in diagnostics and imaging tumors. Nanobodies in addition to their use as therapeutic agents can make highly effective as well as non-invasive molecular imaging reagents Fig. 2. Also due to their high penetration, quick elimination, low immunogenicity, and easy production and selection, nanobodies can be used to produce diagnostic tools [67, 68, 69]. To increase the chances of survival, it’s essential to diagnose tumors very early. Due to their small size, high stability, high target specificity, and affinity nanobodies have been engineered into Nanobody-detective constructs for non-invasive in vivo molecular imaging [70, 71]. Such nanobody constructs developed can sharply reach a maximal contrast between the signal in the pathological tissues and that in healthy tissues [68, 71]. For optimal in vivo molecular imaging, sharpness in reaching maximal contrast is vital. Furthermore, nanobodies have a very short half-life and the excess of non-targeting Nanobodies are rapidly cleared from the bloodstream via the kidney and bladder. Their rapid clearance from blood guarantees a high tumor to background ratio early after administering the nanobody probe [72]. Several imaging techniques have been developed to date for clinical application and manifestation, for instance; single-photon emission computed tomography (SPECT), magnetic resonance imaging (MRI), optical, ultrasound, and photoacoustic imaging positron emission tomography (PET), computed tomography (CT) [73].

5. Molecular imaging of cancer using nanobodies

In comparison to the conventional monoclonal antibodies, nanobodies have small size and very low molecular weight, are exceedingly strategic especially in the field of molecular imaging because it facilitates rapid tumor accumulation, homogenous distribution as well as efficient blood clearance, contributing to high tumor-to-background ratios [74]. Besides, due to their high specificity, nanobodies in conjugation with several kinds of imaging agents provide their use as safe [74, 75]. Various imaging techniques developed that use nanobodies for imaging tumors include; SPECT, PET, etc. Single-photon emission computed tomography (SPECT) is a $\gamma$ -ray based technique where nanobodies are conjugated to radionuclides such as ${}^{\text{99m}}$ Tc, ${}^{111}$ In, ${}^{123}$ I, and ${}^{177}$ Lu, etc. Equally, the positron-emitting radioisotopes like ${}^{68}$ Ga, ${}^{124}$ I, or ${}^{89}$ Zr are used for positron emission tomography (PET) Table 1 [76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87].

Table 1
List of nanobody probes used in cancer imaging

Target	Nanobody	Imaging modality (label)	Disease model	References
HER-2	2Rs15d	SPECT ( ${}^{\text{99m}}$ Tc)	Colon carcinoma (LS174T), Breast cancer (SKBR3), Human Ovarian cancer (SKOV3)	[93]
	2Rs15d	PET ( ${}^{68}$ Ga)	Ovarian cancer (SKOV3)	[82]
	11A4	Optical (IRDye800CW)	Breast cancer	[67]
HGF	1E2 and 6E10	PET ( ${}^{89}$ Zr)	Glioblastoma	[89]
EGFR	8B6	SPECT ( ${}^{\text{99m}}$ Tc)	Epidermoid carcinoma Prostate carcinoma	[83]
	7C12 7D12	SPECT ( ${}^{\text{99m}}$ Tc) PET ( ${}^{68}$ Ga) Optical (IRDye800CW)	Epidermoid carcinoma	[84-86] [91,92]
VCAM-1	cAbVCAM1-5	Ultrasound (microbubble)	Adenocarcinoma (MC38)	[90]
CEA	CEA1	SPECT ( ${}^{\text{99m}}$ Tc)	Colon adenocarcinoma (LS174)	[88]
MMR	$\alpha$ -MMR	SPECT ( ${}^{\text{99m}}$ Tc)	Mammary adenocarcinoma, Lung carcinoma	[87]

Figure 3.

Positron emission tomography (PET) and single photon emission computed tomography (SPECT) images obtained using nanobodies that are labelled with distinct radionuclides in preclinical and clinical studies. I. Uptake of ${}^{68}$ Ga-HER2-Nanobody in primary breast carcinoma lesions (arrows) on PET/CT images (top) and PET images (bottom). (A) Patient showed highest tracer uptake. (B) Patient showed modest tracer uptake, which was effortlessly visible from background. (C) Patient showed no uptake, with CT showing marker clip at tumor region. Adapted from [89]. II. Uptake of ${}^{68}$ Ga-HER2-Nanobody in metastatic lesions on PET/CT images (top) and PET images (bottom). (A) Patient, with invaded lymph nodes in mediastinum and left hilar region. (B) Patient with bone metastasis in pelvis. Adapted from [89]. III. SPECT and micro-CT images of transverse, coronal, and sagittal views of fused pinhole of mice bearing A431 and R1M xenografts. A431 (A) and R1M (C) tumors injected with ${}^{\text{99m}}$ Tc-7C12. A431 (B) and R1M (D) tumors injected with ${}^{\text{99m}}$ Tc-7D12. Images were acquired at 1 h after injection. Adapted from [85]. IV. Micro-SPECT/CT images obtained in HER2 $+$ tumor models BT474/M1 (A) and SKOV-3 (B), 1, 4, and 24 hours after injection of ${}^{\text{[131I]}}$ -2Rs15d. Accumulation of radioactivity was observed in kidneys, bladder, and tumor, indicated by white arrows. Adapted from [94]. V. Representative maximum-intensity-projection images at 10, 60, and 90 min after injection of ${}^{68}$ Ga-HER2-Nanobody for different mass subgroups. (A) Patient 4, injected with 0.01 mg of ${}^{68}$ Ga-HER2-Nanobody. (B) Patient 12, injected with 0.1 mg. (C) Patient 17, injected with 1.0 mg. Adapted from [89].

Figure 4.

Schematic representation of different aptamers in tumor diagnostics.

Among the numerous cancer-specific receptors, EGFR and HER2 represent two interesting targets for tumor visualization [79, 88, 76, 89, 90, 91, 92]. In the radio-immunodetection of EGFR overexpressing tumors, 8B6 a ${}^{\text{99m}}$ Tc radiolabeled nanobody developed against EGFR via SPECT showed promising results [77]. Likewise, some studies have reported that 8B6 nanobody is very effective in detecting human epidermoid carcinoma and human prostate carcinoma. Alternatively, ${}^{89}$ Zr labeled 1E2 and 6E10, albumin coupled nanobodies have also been developed against hepatocyte growth factor (HGF), a prominent growth factor involved in invasion and metastasis in different cancer types [93]. Using PET imaging, several xenograft studies of U87 MG glioblastoma have demonstrated the effectiveness of such nanobodies in visualizing HGF $+$ tumors. The nanobodies upon administration showed uniform tumor distribution and also suppressed tumor growth [83]. Movahedi et al. developed nanobody constructs against the macrophage mannose receptor MMR, highly expressed by macrophages in the tumor microenvironment. This strategy serves as a substitute to image the tumor stroma, especially the hypoxic areas [81]. However, it has been reported that ${}^{\text{99m}}$ Tc-labeled anti-MMR nanobodies are used to visualize TAMs accumulated highly in the liver and spleen (expressing MMR), in comparison to tumor accumulation. Although by the administration of an excess of unlabelled bivalent anti-MMR nanobody, eliminates extratumoral signals while maintaining the targeting of tumor-associated MMR-positive cells solved the problem Fig. 3 [89, 81, 85, 94].

Recently, ${}^{68}$ Ga-NOTA anti-HER2 nanobodies showing promising results in nanobody-based imaging agent for iPET imaging [76]. Evaluation of the ${}^{68}$ Ga-coupled anti-HER2 nanobody at the preclinical stage has demonstrated imperative results and a good toxicological profile with low radiation burden, enabling this construct to enter phase I clinical trials for humans [89]. In terms of efficacy and tracer accumulation, this nanobody in phase I clinical trials showed a good record.

Apart from this, no adverse effects or immunogenicity against the administrated nanobody were detected, representing this construct to be appropriate to enter phase II clinical trials [89]. Using a nanobody NJB2, specific for an alternatively spliced domain of fibronectin, recently have been exploited for extracellular matrix (ECM) targeting for non-invasive imaging of tumor progression, metastasis, and fibrosis. This study has revealed that in in vivo immuno-PET/CT imaging, NJB2 helps in the detection of primary tumors and metastatic sites with excellent specificity in multiple models of breast cancer, including human and mouse triple-negative breast cancer, as well as in melanoma. Additionally, NJB2 could detect not only PDAC tumors but also early pancreatic lesions known as; pancreatic intraepithelial neoplasias, representing a very challenging innovation in comparison to being detected by any current imaging modalities, with excellent clarity and signal-to-noise ratios that outperformed conventional 2-fluorodeoxyglucose PET/CT imaging [95]. Also, OA-cb6 nanobody with ${}^{99}$ mTc (CO)3 ${}^{+}$ which was developed against EGFR have been evaluated in the A431 human epidermal carcinoma cell line and demonstrated significant radiolabeling and radiochemical purity. Also, numerous in vivo studies have revealed favorable bio-distribution of nanobodies in tumor-to-muscle ratio at 4-hr post injection which suggested that cb6 nanobody with ${}^{99}$ mTc (CO)3 ${}^{+}$ is a promising radiolabeled biomolecule for tumor imaging in cancers with high EGFR overexpression [96].

Table 2

List of aptamers developed against specific markers expressed by tumor cells

Aptamers	Target cells	Target	References
SYL3C	MCF7 (breast cancer)	EpCAM	[117]
A15	Hep3B (liver cancer)	CD133	[118]
Apt928	SKOV-3 (ovarian cancer)	CD70	[119]
A10	LNCaP (prostate cancer)	PSMA	[120]
GBI-10	U251 (glioblastoma)	Tenascin-C	[121]
Apt1	A549 (lung cancer)	CD44	[122]
KH1C12 aptamer	HL-60 (leukemia)	KH1C12	[123]
CD24 aptamer	HT-29 (colon cancer)	CD24	[124]
TD05	Ramos (Burkett’s lymphoma)	IGHM	[125]

6. Aptamers in cancer diagnostics

The term aptamer was coined by Ellington et al. in 1990 and has been derived from a Latin word ‘aptus’ which means fit [97]. Aptamers are single-stranded DNA, RNA, or altered nucleic acid sequences that have a high affinity for target-specific binding developed by SELEX i.e. systemic evolution of ligands by exponential enrichment technology [98, 99]. Because of their high specificity, stability, and non-immunogenicity, aptamers are well-thought-out to be the most promising therapeutic agents which can specifically bind to their targets. Because of their unique three-dimensional structure, aptamers can bind to the target with high specificity and affinity. Few aptamers have a unique function as regulatory proteins and can regulate the function of target proteins via binding to such proteins. There are diverse targets for aptamers some of which include; proteins, ions, cells etc. [100, 101]. Aptamers are termed as chemical antibodies that can be produced at low cost with easy modifications. In comparison to antibodies, aptamers have several applications: high specificity, stronger affinity with the target proteins, can be easily prepared and modified, high stability, and stress-free storage [102]. Until now, a range of aptamers have been screened in diagnostics and therapeutics [103]. Due to the limitations in traditional cancer treatments and diagnostics, it is vital to discover effective methods for cancer diagnosis, early detection, and treatment strategies [104, 105] and the distinctive properties of aptamers have contributed to the rapid analysis, diagnosis as well as treatment of cancer Fig. 4 [106]. Different modifications in aptamers are being applied regularly to make them more versatile, such as with biotin, fluorescent dyes, or even radionuclides [107]. Aptamers are capable to deliver drugs, proteins, or nucleic acids more efficiently into specific structures in the cells via conjugation to siRNAs, nanobodies, or drug molecules reducing the toxic side effects [108, 109, 110]. With the help of aptamers that can recognize specific antigens or biomarkers on the tumor cells in combination with nanoparticles, actively targeted aggregation of nanoparticles can be achieved in the tumor cells with the reduction in toxicity to normal surrounding cells [111].

Presently, aptamer-nanoparticle conjugates have proved significant applications in cancer diagnosis and therapy. Such conjugates have been widely applied for providing the early diagnosis as well as targeted therapy with high affinity biomarkers in the detection of circulating tumor cells (CTCs), introducing a novel outlook for personalized medicine of cancer [112, 113, 114]. The development of cell-SELEX aptamer screening technology is used to categorize cancer cells on the basis of cell surface markers that are overexpressed or altered due to multiple oncogenic mutations Table 2 [115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125].

The use of aptamers represents a class of ligands that are highly specific as well as having a high affinity towards their target [126, 98]. Presently, a range of aptamers have been screened that can target tumor cells; for example; A10, PMSA aptamer (anti-prostate-specific membrane antigen) [127], AS1411, anti-nucleolin aptamer [128, 129], EpCAM, anti-epithelial cell adhesion molecule aptamer [130, 131], MUC1, anti-mucin1 aptamer [132], Sgc8, anti-protein tyrosine kinase 7 aptamer (PTK7) [133, 134] etc.

Cancer being the second leading cause of death throughout the world [135, 1], therefore an accurate diagnostic technology will show a positive clinical application, which will help clinicians to suggest early treatment strategies, evaluation of treatment effects, monitoring tumor relapse and metastasis as well as assessment of prognosis. Hence aptamers due to their high affinity and specificity to targets hold an apparent advantage in stability, modification and cost production. There is a vast application of aptamers in the field of cancer diagnosis. Circulating tumor cells (CTCs) represent specific tumor markers that are secreted by tumor cells into the blood circulation act as a good target for liquid biopsy [136]. Thus, the delicate recognition of cancer cells plays an important role in diagnosis as well as prognosis [137]. The detection of CTCs in the early stages of cancer in an accurate and efficient concentration will help to monitor the condition and progression of cancer among patients [138]. Recently several methods have been applied for CTCs detection in conjugation with different signal reporting technologies like; fluorescence, magnetic, calorimetric, and electrochemical technology [139, 140, 142, 142]. For example, using a DNA network comprising repeating adhesive aptamer domains, Karnik et al. had developed a podium to isolate and capture CTCs. Similarly, Kashefi-kheyrabadi et al. had established an electrochemical technique for CTCs detection of liver cancer using a liver cancer HepG2 cell-specific aptamer conjugated to a gold plane electrode [140]. For isolation of cancer cells from blood, Fan et al. had developed a podium that links multivalent DNA aptamer nanoparticles with microfluidic devices [143]. Likewise, a dual-aptamer-targeted high-sensitivity CTCs detection podium have been established by Wang et al. conjugating VEGF aptamers with magnetic beads for capturing and concentrating CTCs, using MUC1aptamer-conjugated Pt-Au nanoparticles. Aptamer-functionalized nanostructures have also been developed for cell hook and isolation.

Since recent times, molecular imaging is of great importance in disease detection, observation and prognosis [144]. Aptamers in combination with imaging molecules, like; radionuclides, fluorescent molecules etc. are fetching a prominent tool in cancer diagnosis [145, 146, 147]. A number of imaging technologies used in tumor diagnosis include; computed tomography (CT), luminescence imaging, radionuclide-based positron emission tomography (PET), magnetic resonance imaging (MRI), and single photon emission computed tomography (SPECT). IRD800CW labeled CD30 aptamer have been used for in vivo imaging of lymphoma [148], Cy5 labeled pancreatic cancer specific aptamer have been used for in vivo imaging of pancreatic cancer [149], AS1411 aptamer coupled with blood-brain barrier targeting peptide for in vivo imaging of gliomas [150], etc. In addition to imaging with fluorescent molecules, aptamers in conjugation to magnetic beads can enhance MRI [147]. For example, vascular endothelial growth factor receptor 2 (VEGFR2) aptamer conjugated with magnetic nanomaterials for glioma MRI imaging [151]. Also, Epidermal adhesion molecule (EpCAM) aptamer in conjugation with magnetic nanomaterials is used for MRI imaging of gastric cancer [152], etc. All of these conjugated aptamers significantly improved the tumor-targeted imaging capability, sensitivity as well as biocompatibility, and ultimately reduced the cytotoxicity, advancing the clinical application potential of MRI. In current years, aptamers have shown application features superior to antibodies and are being widely used in immunohistochemical analysis (IHC) analysis of tumor cells. The ICH analysis of formalin-fixed-paraffin-embedded lymphoma was performed by Zu’s group, who found that CD30 aptamer showed almost the same staining pattern as CD30 antibody. Unlike antibodies, aptamers do not cause non-specific staining of necrotic areas in tissue samples when applied to ICH [153]. Moreover, Li et al. had screened a group of aptamers that can specifically identify metastatic lymph node tissues in colon cancer. Using aptamers as probes, IHC analysis could specifically identify colon cancer tissues showing lymph node tissues with colon metastasis. no such signal was stated in non-metastatic colon cancer tissues, or other control tissues, which suggest that aptamers recognize the target related to the process of metastasis. This can be used in the early diagnosis of cancer [154]. Apart from this, a number of chemical drugs are being used to kill cancerous cells, the only drawback is they destroy normal tissues causing severe adverse reactions. As a result, targeted drug delivery is the key approach for current cancer treatment. And aptamers have grown into a novel path in targeted drug therapeutics because of their unique biological and chemical properties [155] viz. aptamer-drug conjugates (AptDC), aptamer-functionalized nanoparticles, therapeutic aptamers, and aptamer mediated immunotherapy [156].

7. Conclusion

Globally, the high mortality rate due to cancer is still challenging irrespective of advances in treatment including radiotherapy, chemotherapy, and immunotherapy. The use of imaging biomarkers in cancer diagnosis has paved the way for personalized medicine with the accuracy and predictive diagnosis and treatment alternatives. Advances in radiomics, nanobodies, and aptamers in diagnosis and tumor imaging will open new doors for precision treatment and increase the overall survival of cancer patients. Irrespective of their vast applications in cancer biology, they still need to improve target efficacy as well as affinity. Besides their modifications with other drugs, such technologies can be conjugated with several imaging agents which could help in efficient detection of cancer type as well as monitor drug efficacy and disease progression. We believe that with the continuous advancements in such innovative technologies, these will play an important role in future oncological applications.

Footnotes

Acknowledgments

The author acknowledges support and cooperation of Department of Radiological Sciences and Medical Imaging, College of Applied Medical Sciences, Majmaah University, Almajmaah-11953, Kingdom of Saudi Arabia.

Conflict of interest

The author declares that has no conflict of interest.

Funding

No funding was received for the said project.

References

Siegel

R.L.

Miller

K.D.

and Jemal

, Cancer statistics, 2019, CA: A Cancer Journal for Clinicians 69(1) (2019), 7–34.

Murtaza

Hichami

Khan

A.S.

Ghiringhelli

and Khan

N.A.

, Alteration in taste perception in cancer: causes and strategies of treatment, Frontiers in Physiology 8 (2017), 134.

Miller

K.D.

Nogueira

Mariotto

A.B.

Rowland

J.H.

Yabroff

K.R.

Alfano

C.M.

Jemal

Kramer

J.L.

and Siegel

R.L.

, Cancer treatment and survivorship statistics, 2019, CA: A Cancer Journal for Clinicians 69(5) (2019), 363-385.

Hafeez

Urooj

Saleem

Gillani

Shaheen

Qazi

M.H.

Naseer

M.I.

Iqbal

Ansari

S.A.

and Haque

, BAD, a proapoptotic protein, escapes ERK/RSK phosphorylation in deguelin and siRNA-treated hela cells, PLoS One 11(1) (2016), e0145780.

M.A.

Hamdani

S.S.

Sheikh

B.A.

and Mehraj

, Recent advances in metabolites from medicinal plants in cancer prevention and treatment, Current Immunology Reviews 15(2) (2019), 185–201.

Yates

L.R.

Knappskog

Wedge

Farmery

J.H.R.

Gonzalez

Martincorena

Alexandrov

L.B.

Van Loo

Haugland

H.K.

and Lilleng

P.K.

, Genomic evolution of breast cancer metastasis and relapse, Cancer Cell 32(2) (2017), 169–184.

Hassan

E.M.

and DeRosa

M.C.

, Recent advances in cancer early detection and diagnosis: role of nucleic acid based aptasensors, TrAC Trends in Analytical Chemistry 124 (2020), 115806.

Peng

Chen

Farshidfar

Lorenzi

P.L.

Wang

Cheng

Tan

Mojumdar

and Du

, Molecular characterization and clinical relevance of metabolic expression subtypes in human cancers, Cell Reports 23(1) (2018), 255–269.

Mahasneh

Al-Shaheri

and Jamal

, Molecular biomarkers for an early diagnosis, effective treatment and prognosis of colorectal cancer: current updates, Experimental and Molecular Pathology 102(3) (2017), 475–483.

10.

Gillies

R.J.

and Schabath

M.B.

, Radiomics improves cancer screening and early detection, Cancer Epidemiology and Prevention Biomarkers 29(12) (2020), 2556–2567.

11.

Ruiz Ciancio

Vargas

M.R.

Thiel

W.H.

Bruno

M.A.

Giangrande

P.H.

and Mestre

M.B.

, Aptamers as diagnostic tools in cancer, Pharmaceuticals 11(3) (2018), 86.

12.

Laptoš

and Omersel

, The importance of handling high-value biologicals: physico-chemical instability and immunogenicity of monoclonal antibodies, Experimental and Therapeutic Medicine 15(4) (2018), 3161–3168.

13.

Chen

Liu

Zhong

Zhang

Liao

Liu

and Qiu

, Advances in the development of aptamer drug conjugates for targeted drug delivery, Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology 9(3) (2017), e1438.

14.

Muyldermans

, Nanobodies: natural single-domain antibodies, Annual Review of Biochemistry 82 (2013), 775–797.

15.

Mir

M.A.

Mehraj

Sheikh

B.A.

and Hamdani

S.S.

, Nanobodies: the “magic bullets” in therapeutics, drug delivery and diagnostics, Human Antibodies 28(1) (2020), 29–51.

16.

Yang

E.Y.

and Shah

, Nanobodies: next generation of cancer diagnostics and therapeutics, Frontiers in Oncology 10 (2020), 1182.

17.

Huang

Muyldermans

and Saerens

, Nanobodies® proficient tools in diagnostics, Expert Review of Molecular Diagnostics 10(6) (2010), 777–785.

18.

Valdora

Houssami

Rossi

Calabrese

and Tagliafico

A.S.

, Rapid review: radiomics and breast cancer, Breast Cancer Research and Treatment 169(2) (2018), 217–229.

19.

Fave

Mackin

D.S.

Lee

Yang

and Zhang

, Computational resources for radiomics, Translational Cancer Research 5(4) (2016), 340–348.

20.

Yip

S.S.F.

and Aerts

H.J.W.L.

, Applications and limitations of radiomics, Physics in Medicine & Biology 61(13) (2016), R150.

21.

Kumar

Basu

Berglund

Eschrich

S.A.

Schabath

M.B.

Forster

Aerts

H.J.W.L.

Dekker

and Fenstermacher

, Radiomics: the process and the challenges, Magnetic Resonance Imaging 30(9) (2012), 1234–1248.

22.

Lambin

Rios-Velazquez

Leijenaar

Carvalho

Van Stiphout

R.G.P.M.

Granton

Zegers

C.M.L.

Gillies

Boellard

and Dekker

, Radiomics: extracting more information from medical images using advanced feature analysis, European Journal of Cancer 48(4) (2012), 441–446.

23.

Garriga

Milà

Mir

Al-Baradie

Huertas

Castejon

Casas

Badenes

Giménez

and Font

, 123I-FP-CIT SPECT imaging in early diagnosis of dementia in patients with and without a vascular component, Frontiers in Systems Neuroscience 9 (2015), 99.

24.

Chen

Yang

Zhang

Luo

and Li

, Radiomics: an overview in lung cancer management – a narrative review, Annals of Translational Medicine 8(18) (2020).

25.

Jethanandani

Lin

T.A.

Volpe

Elhalawani

Mohamed

A.S.R.

Yang

and Fuller

C.D.

, Exploring applications of radiomics in magnetic resonance imaging of head and neck cancer: a systematic review, Frontiers in Oncology 8 (2018), 131.

26.

Park

J.E.

and Kim

H.S.

, Radiomics as a quantitative imaging biomarker: practical considerations and the current standpoint in neuro-oncologic studies, Nuclear Medicine and Molecular Imaging 52(2) (2018), 99–108.

27.

Liu

Wang

Di Dong

J.W.

Fang

Zhou

Sun

Wang

and Tian

, The applications of radiomics in precision diagnosis and treatment of oncology: opportunities and challenges, Theranostics 9(5) (2019), 1303.

28.

Bai

Lin

Tian

Shi

Cheng

Haacke

E.M.

Hong

Zhou

and Wang

, Grading of gliomas by using monoexponential, biexponential, and stretched exponential diffusion-weighted MR imaging and diffusion kurtosis MR imaging, Radiology 278(2) (2016), 496–504.

29.

Kickingereder

Burth

Wick

Götz

Eidel

Schlemmer

H.-P.

Maier-Hein

K.H.

Wick

Bendszus

and Radbruch

, Radiomic profiling of glioblastoma: identifying an imaging predictor of patient survival with improved performance over established clinical and radiologic risk models, Radiology 280(3) (2016), 880–889.

30.

Itakura

Achrol

A.S.

Mitchell

L.A.

Loya

J.J.

Liu

Westbroek

E.M.

Feroze

A.H.

Rodriguez

Echegaray

and Azad

T.D.

, Magnetic resonance image features identify glioblastoma phenotypic subtypes with distinct molecular pathway activities, Science Translational Medicine 7(303) (2015), 303ra138-303ra138.

31.

Grossmann

Narayan

Chang

Rahman

Abrey

Reardon

D.A.

Schwartz

L.H.

Wen

P.Y.

Alexander

B.M.

and Huang

, Quantitative imaging biomarkers for risk stratification of patients with recurrent glioblastoma treated with bevacizumab, Neuro-oncology 19(12) (2017), 1688–1697.

32.

Papp

Pötsch

Grahovac

Schmidbauer

Woehrer

Preusser

Mitterhauser

Kiesel

Wadsak

and Beyer

, Glioma survival prediction with combined analysis of in vivo 11C-MET PET features, ex vivo features, and patient features by supervised machine learning, Journal of Nuclear Medicine 59(6) (2018), 892–899.

33.

Ren

Tian

Yuan

Dong

Shi

and Tao

, Magnetic resonance imaging based radiomics signature for the preoperative discrimination of stage I-II and III-IV head and neck squamous cell carcinoma, European Journal of Radiology 106 (2018), 1–6.

34.

Leijenaar

R.T.H.

Bogowicz

Jochems

Hoebers

F.J.P.

Wesseling

F.W.R.

Huang

S.H.

Chan

Waldron

J.N.

O’Sullivan

and Rietveld

, Development and validation of a radiomic signature to predict HPV (p16) status from standard CT imaging: a multicenter study, The British Journal of Radiology 91(1086) (2018), 20170498.

35.

Mir

M.A.

and Mehraj

, Double-crosser of the immune system: macrophages in tumor progression and metastasis, Current Immunology Reviews 15(2) (2019), 172–184.

36.

Mir

M.A.

Qayoom

Mehraj

Nisar

Bhat

and Wani

N.A.

, Targeting different pathways using novel combination therapy in triple negative breast cancer, Current Cancer Drug Targets 20(8) (2020), 586–602. doi: 10.2174/1570163817666200518081955.

37.

Antropova

Huynh

B.Q.

and Giger

M.L.

, A deep feature fusion methodology for breast cancer diagnosis demonstrated on three imaging modality datasets, Medical Physics 44(10) (2017), 5162–5171.

38.

Antunovic

Gallivanone

Sollini

Sagona

Invento

Manfrinato

Kirienko

Tinterri

Chiti

and Castiglioni

, [18 F] FDG PET/CT features for the molecular characterization of primary breast tumors, European Journal of Nuclear Medicine and Molecular Imaging 44(12) (2017), 1945–1954.

39.

Park

Bang

J.-I.

Kim

E.-K.

and Lee

H.-Y.

, Metabolic radiomics for pretreatment 18 F-FDG PET/CT to characterize locally advanced breast cancer: histopathologic characteristics, response to neoadjuvant chemotherapy, and prognosis, Scientific Reports 7(1) (2017), 1–11.

40.

Guo

Zhu

Lan

Yang

Drukker

Morris

E.A.

Burnside

E.S.

Whitman

G.J.

and Giger

M.L.

, Prediction of clinical phenotypes in invasive breast carcinomas from the integration of radiomics and genomics data, Journal of Medical Imaging 2(4) (2015), 041007.

41.

Saha

Harowicz

M.R.

Grimm

L.J.

Kim

C.E.

Ghate

S.V.

Walsh

and Mazurowski

M.A.

, A machine learning approach to radiogenomics of breast cancer: a study of 922 subjects and 529 DCE-MRI features, British Journal of Cancer 119(4) (2018), 508–516.

42.

Chan

H.M.

van der Velden

B.H.M.

Loo

C.E.

and Gilhuijs

K.G.A.

, Eigentumors for prediction of treatment failure in patients with early-stage breast cancer using dynamic contrast-enhanced MRI: a feasibility study. Physics in Medicine & Biology 62(16) (2017), 6467.

43.

Braman

N.M.

Etesami

Prasanna

Dubchuk

Gilmore

Tiwari

Plecha

and Madabhushi

, Intratumoral and peritumoral radiomics for the pretreatment prediction of pathological complete response to neoadjuvant chemotherapy based on breast DCE-MRI, Breast Cancer Research 19(1) (2017), 1–14.

44.

Shaikh

F.A.

Kolowitz

B.J.

Awan

Aerts

H.J.

von Reden

Halabi

Mohiuddin

S.A.

Malik

Shrestha

R.B.

and Deible

, Technical challenges in the clinical application of radiomics, JCO Clinical Cancer Informatics 1 (2017), 1–8.

45.

Limkin

E.J.

Sun

Dercle

Zacharaki

E.I.

Robert

Reuzé

Schernberg

Paragios

Deutsch

and Ferté

, Promises and challenges for the implementation of computational medical imaging (radiomics) in oncology, Annals of Oncology 28(6) (2017), 1191–1206.

46.

Kumar

Chung

A.G.

Shaifee

M.J.

Khalvati

Haider

M.A.

and Wong

, Discovery radiomics for pathologically-proven computed tomography lung cancer prediction, in: Springer, 2017, pp. 54–62.

47.

Shen

Zhou

Yang

Dong

Yang

Zang

and Tian

, Multi-crop convolutional neural networks for lung nodule malignancy suspiciousness classification, Pattern Recognition 61 (2017), 663–673.

48.

Mattonen

S.A.

Tetar

Palma

D.A.

Senan

and Ward

A.D.

, Automated texture analysis for prediction of recurrence after stereotactic ablative radiation therapy for lung cancer, International Journal of Radiation Oncology Biology Physics 93(3) (2015), S5–S6.

49.

Mattonen

S.A.

Palma

D.A.

Haasbeek

C.J.A.

Senan

and Ward

A.D.

, Early prediction of tumor recurrence based on CT texture changes after stereotactic ablative radiotherapy (SABR) for lung cancer, Medical Physics 41(3) (2014), 033502.

50.

Fave

Zhang

Yang

Mackin

Balter

Gomez

Followill

Jones

A.K.

Stingo

and Liao

, Delta-radiomics features for the prediction of patient outcomes in non-small cell lung cancer, Scientific Reports 7(1) (2017), 1–11.

51.

Coroller

T.P.

Agrawal

Narayan

Hou

Grossmann

Lee

S.W.

Mak

R.H.

and Aerts

H.J.W.L.

, Radiomic phenotype features predict pathological response in non-small cell lung cancer, Radiotherapy and Oncology 119(3) (2016), 480–486

52.

Song

Shi

Dong

Fang

Zhong

Wang

Huang

Liu

and Cheng

, A new approach to predict progression-free survival in stage IV EGFR-mutant NSCLC patients with EGFR-TKI therapy, Clinical Cancer Research 24(15) (2018), 3583–3592.

53.

Aerts

H.J.W.L.

Velazquez

E.R.

Leijenaar

R.T.H.

Parmar

Grossmann

Carvalho

Bussink

Monshouwer

Haibe-Kains

and Rietveld

, Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach, Nature Communications 5(1) (2014), 1–9.

54.

Song

Liu

Zhong

Huang

Dong

Liang

and Tian

, Non-small cell lung cancer: quantitative phenotypic analysis of CT images as a potential marker of prognosis, Scientific Reports 6 (2016), 38282.

55.

Balagurunathan

Wang

Kumar

Grove

Hawkins

Kim

Goldgof

D.B.

Hall

L.O.

and Gatenby

R.A.

, Reproducibility and prognosis of quantitative features extracted from CT images, Translational Oncology 7(1) (2014), 72–87.

56.

Sahin

Tureci

Koslowski

and Mitnacht-Kraus

, Monoclonal antibodies for treatment of cancer, Google Patents, 2015.

57.

Lee

J.Y.

Lee

H.T.

Shin

Chae

Choi

Kim

S.H.

Lim

Heo

T.W.

Park

K.Y.

and Lee

Y.J.

, Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy, Nature Communications 7(1) (2016), 1–10.

58.

Sheikh

B.A.

Bhat

B.A.

Mehraj

Mir

Hamadani

and Mir

M.A.

, Development of new therapeutics to meet the current challenge of drug resistant tuberculosis, Current Pharmaceutical Biotechnology, 2020.

59.

Jain

R.K.

, Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors, Cancer Research 50(3 Supplement) (1990), 814s–819s.

60.

Wesolowski

Alzogaray

Reyelt

Unger

Juarez

Urrutia

Cauerhff

Danquah

Rissiek

and Scheuplein

, Single domain antibodies: promising experimental and therapeutic tools in infection and immunity, Medical Microbiology and Immunology 198(3) (2009), 157–174.

61.

Moradi

Pourseif

M.M.

Jafari

Parvizpour

and Omidi

, Nanobody-based therapeutics against colorectal cancer: Precision therapies based on the personal mutanome profile and tumor neoantigens, Pharmacological Research, 2020, 104790.

62.

Hamers-Casterman

Atarhouch

Muyldermans

Robinson

Hammers

Songa

E.B.

Bendahman

and Hammers

, Naturally occurring antibodies devoid of light chains, Nature 363(6428) (1993), 446–448.

63.

Kolkman

J.A.L.

and Debbie

, Nanobodies – from llamas to therapeutic proteins, Drug Discovery Today: Technologies 7(2) (2010), e139–e146.

64.

Muyldermans

Atarhouch

Saldanha

Barbosa

and Hamers

, Sequence and structure of VH domain from naturally occurring camel heavy chain immunoglobulins lacking light chains, Protein Engineering, Design Selection 7(9) (1994), 1129–1135.

65.

Mir

M.A.

and Agrewala

J.N.

, Signaling through CD80: an approach for treating lymphomas, Expert Opinion on Therapeutic Targets 12(8) (2008), 969–979.

66.

Mir

M.A.

and Agrewala

J.N.

, Influence of CD80 and CD86 co-stimulation in the modulation of the activation of antigen presenting cells, Current Immunology Reviews 3(3) (2007), 160–169.

67.

Mujić-Delić

de Wit

R.H.

Verkaar

and Smit

M.J.

, GPCR-targeting nanobodies: attractive research tools, diagnostics, and therapeutics, Trends in Pharmacological Sciences 35(5) (2014), 247–255.

68.

Zhan

Gedroyc

and Xu

X.Y.

, The effect of tumour size on drug transport and uptake in 3-D tumour models reconstructed from magnetic resonance images, PloS One 12(2) (2017).

69.

Kijanka

Warnders

F.-J.

El Khattabi

Lub-de Hooge

van Dam

G.M.

Ntziachristos

de Vries

Oliveira

and en Henegouwen

P.M.P.v.B.

, Rapid optical imaging of human breast tumour xenografts using anti-HER2 VHHs site-directly conjugated to IRDye 800CW for image-guided surgery, European Journal of Nuclear Medicine and Molecular Imaging 40(11) (2013), 1718–1729.

70.

Saeed

A.F.U.H.

Wang

Ling

and Wang

, Antibody engineering for pursuing a healthier future, Frontiers in Microbiology 8 (2017), 495.

71.

Van Audenhove

and Gettemans

, Nanobodies as versatile tools to understand, diagnose, visualize and treat cancer, EBioMedicine 8 (2016), 40–48.

72.

Debie

Devoogdt

and Hernot

, Targeted nanobody-based molecular tracers for nuclear imaging and image-guided surgery, Antibodies 8(1) (2019), 12.

73.

Lecocq

De Vlaeminck

Hanssens

D’Huyvetter

Raes

Goyvaerts

Keyaerts

Devoogdt

and Breckpot

, Theranostics in immuno-oncology using nanobody derivatives, Theranostics 9(25) (2019), 7772.

74.

Arbabi-Ghahroudi

, Camelid single-domain antibodies: historical perspective and future outlook, Frontiers in Immunology 8 (2017), 1589.

75.

Khodabakhsh

Behdani

Rami

and Kazemi-Lomedasht

, Single-domain antibodies or nanobodies: a class of next-generation antibodies, International Reviews of Immunology 37(6) (2018), 316–322.

76.

Xavier

Vaneycken

D’huyvetter

Heemskerk

Keyaerts

Vincke

Devoogdt

Muyldermans

Lahoutte

and Caveliers

, Synthesis, preclinical validation, dosimetry, and toxicity of 68Ga-NOTA-anti-HER2 nanobodies for iPET imaging of HER2 receptor expression in cancer, Journal of Nuclear Medicine 54(5) (2013), 776–784.

77.

Huang

Gainkam

L.O.T.

Caveliers

Vanhove

Keyaerts

De Baetselier

Bossuyt

Revets

and Lahoutte

, SPECT imaging with 99m Tc-labeled EGFR-specific nanobody for in vivo monitoring of EGFR expression, Molecular Imaging and Biology 10(3) (2008), 167–175.

78.

Tchouate Gainkam

L.O.

Caveliers

Devoogdt

Vanhove

Xavier

Boerman

Muyldermans

Bossuyt

and Lahoutte

, Localization, mechanism and reduction of renal retention of technetium-99m labeled epidermal growth factor receptor-specific nanobody in mice, Contrast Media & Molecular Imaging 6(2) (2011), 85–92.

79.

Vosjan

M.J.W.D.

Perk

L.R.

Roovers

R.C.

Visser

G.W.M.

Stigter-van Walsum

en Henegouwen

P.M.P.v.B.

and van Dongen

G.A.M.S.

, Facile labelling of an anti-epidermal growth factor receptor nanobody with 68 Ga via a novel bifunctional desferal chelate for immuno-PET, European Journal of Nuclear Medicine and Molecular Imaging 38(4) (2011), 753–763.

80.

Oliveira

Van Dongen

G.A.M.S.

Walsum

M.S.-v.

Roovers

R.C.

Stam

J.C.

Mali

Van Diest

P.J.

and van Bergen en Henegouwen

P.M.P.

, Rapid visualization of human tumor xenografts through optical imaging with a near-infrared fluorescent anti-epidermal growth factor receptor nanobody, Molecular Imaging 11(1) (2012), 7290–2011.

81.

Movahedi

Schoonooghe

Laoui

Houbracken

Waelput

Breckpot

Bouwens

Lahoutte

De Baetselier

and Raes

, Nanobody-based targeting of the macrophage mannose receptor for effective in vivo imaging of tumor-associated macrophages, Cancer Research 72(16) (2012), 4165–4177.

82.

Caveliers

Cortez-Retamozo

Lahoutte

Tchouate Gainkam

L.O.

Hernot

Packeu

Vos

F.D.

Vanhove

Muyldermans

and Baetselier

P.D.

, 99mTc-labeled nanobodies: a new type of targeted probes for imaging antigen expression, Current Radiopharmaceuticals 1(1) (2008), 37–41.

83.

Vosjan

M.J.W.D.

Vercammen

Kolkman

J.A.

Stigter-van Walsum

Revets

and van Dongen

G.A.M.S.

, Nanobodies targeting the hepatocyte growth factor: potential new drugs for molecular cancer therapy, Molecular Cancer Therapeutics 11(4) (2012), 1017–1025.

84.

Hernot

Unnikrishnan

Shevchenko

Cosyns

Broisat

Toczek

Caveliers

Muyldermans

and Lahoutte

, Nanobody-coupled microbubbles as novel molecular tracer, Journal of Controlled Release 158(2) (2012), 346–353.

85.

Gainkam

L.O.T.

Huang

Caveliers

Keyaerts

Hernot

Vaneycken

Vanhove

Revets

De Baetselier

and Lahoutte

, Comparison of the biodistribution and tumor targeting of two 99mTc-labeled anti-EGFR nanobodies in mice, using pinhole SPECT/micro-CT, Journal of Nuclear Medicine 49(5) (2008), 788–795.

86.

Gainkam

L.O.T.

Keyaerts

Caveliers

Devoogdt

Vanhove

Van Grunsven

Muyldermans

and Lahoutte

, Correlation between epidermal growth factor receptor-specific nanobody uptake and tumor burden: a tool for noninvasive monitoring of tumor response to therapy, Molecular Imaging and Biology 13(5) (2011), 940–948.

87.

Vaneycken

Devoogdt

Van Gassen

Vincke

Xavier

Wernery

Muyldermans

Lahoutte

and Caveliers

, Preclinical screening of anti-HER2 nanobodies for molecular imaging of breast cancer, The FASEB Journal 25(7) (2011), 2433–2446.

88.

D’Huyvetter

Vincke

Xavier

Aerts

Impens

Baatout

De Raeve

Muyldermans

Caveliers

and Devoogdt

, Targeted radionuclide therapy with a 177Lu-labeled anti-HER2 nanobody, Theranostics 4(7) (2014), 708.

89.

Keyaerts

Xavier

Heemskerk

Devoogdt

Everaert

Ackaert

Vanhoeij

Duhoux

F.P.

Gevaert

and Simon

, Phase i study of 68Ga-HER2-nanobody for PET/CT assessment of HER2 expression in breast carcinoma, Journal of Nuclear Medicine 57(1) (2016), 27–33.

90.

Massa

Xavier

De Vos

Caveliers

Lahoutte

Muyldermans

and Devoogdt

, Site-specific labeling of cysteine-tagged camelid single-domain antibody-fragments for use in molecular imaging, Bioconjugate Chemistry 25(5) (2014), 979–988.

91.

Pruszynski

Koumarianou

Vaidyanathan

Revets

Devoogdt

Lahoutte

and Zalutsky

M.R.

, Targeting breast carcinoma with radioiodinated anti-HER2 nanobody, Nuclear Medicine and Biology 40(1) (2013), 52–59.

92.

Pruszynski

Koumarianou

Vaidyanathan

Revets

Devoogdt

Lahoutte

Lyerly

H.K.

and Zalutsky

M.R.

, Improved tumor targeting of anti-HER2 nanobody through n-succinimidyl 4-guanidinomethyl-3-iodobenzoate radiolabeling, Journal of Nuclear Medicine 55(4) (2014), 650–656.

93.

Nakamura

Matsumoto

Kiritoshi

Tano

and Nakamura

, Induction of hepatocyte growth factor in fibroblasts by tumor-derived factors affects invasive growth of tumor cells: in vitro analysis of tumor-stromal interactions, Cancer Research 57(15) (1997), 3305–3313.

94.

D’Huyvetter

De Vos

Xavier

Pruszynski

Sterckx

Y.G.J.

Massa

Raes

Caveliers

Zalutsky

M.R.

and Lahoutte

, 131I-labeled anti-HER2 camelid sdAb as a theranostic tool in cancer treatment, Clinical Cancer Research 23(21) (2017), 6616–6628.

95.

Jailkhani

Ingram

J.R.

Rashidian

Rickelt

Tian

Mak

Jiang

Ploegh

H.L.

and Hynes

R.O.

, Noninvasive imaging of tumor progression, metastasis, and fibrosis using a nanobody targeting the extracellular matrix, Proceedings of the National Academy of Sciences 116(28) (2019), 14181–14190.

96.

Piramoon

Hosseinimehr

S.J.

Omidfar

Noaparast

and Abedi

S.M.

, 99mTc-anti-epidermal growth factor receptor nanobody for tumor imaging, Chemical Biology & Drug Design 89(4) (2017), 498–504.

97.

Ellington

A.D.

and Szostak

J.W.

, In vitro selection of RNA molecules that bind specific ligands, Nature 346(6287) (1990), 818–822.

98.

Tuerk

and Gold

, Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase, Science 249(4968) (1990), 505–510.

99.

Osborne

S.E.

Matsumura

and Ellington

A.D.

, Aptamers as therapeutic and diagnostic reagents: problems and prospects, Current Opinion in Chemical Biology 1(1) (1997), 5–9.

100.

Mayer

, The chemical biology of aptamers, Angewandte Chemie International Edition 48(15) (2009), 2672–2689.

101.

Gelinas

A.D.

Davies

D.R.

and Janjic

, Embracing proteins: structural themes in aptamer-protein complexes, Current Opinion in Structural Biology 36 (2016), 122–132.

102.

Huang

Deng

and He

, Progress in selection and biomedical applications of aptamers, Journal of Biomedical Nanotechnology 10(10) (2014), 3043–3062.

103.

Liu

Ali

M.M.

Mahmood

M.A.I.

Labanieh

Iqbal

S.M.

Zhang

Zhao

and Wan

, Nucleic acid aptamers in cancer research, diagnosis and therapy, Chemical Society Reviews 44(5) (2015), 1240–1256.

104.

Smith

R.A.

Andrews

K.S.

Brooks

Fedewa

S.A.

Manassaram-Baptiste

Saslow

Brawley

O.W.

and Wender

R.C.

, Cancer screening in the United States, 2018: a review of current American Cancer Society guidelines and current issues in cancer screening, CA: A Cancer Journal for Clinicians 68(4) (2018), 297–316.

105.

Mir

M.A.

Mehraj

and Sheikh

B.A.

, Recent advances in chemotherapeutic implications of deguelin: a plant-derived retinoid, The Natural Products Journal 10 (2020), 1.

106.

Bruno

J.G.

, Predicting the uncertain future of aptamer-based diagnostics and therapeutics, Molecules 20(4) (2015), 6866–6887.

107.

Xuan

Peng

Deng

Peng

Kuai

Jin

Liu

and Wang

, A basic insight into aptamer-drug conjugates (ApDCs), Biomaterials 182 (2018), 216–226.

108.

Bagalkot

Farokhzad

O.C.

Langer

and Jon

, An aptamer-doxorubicin physical conjugate as a novel targeted drug-delivery platform, Angewandte Chemie International Edition 45(48) (2006), 8149–8152.

109.

Farokhzad

O.C.

Cheng

Teply

B.A.

Sherifi

Jon

Kantoff

P.W.

Richie

J.P.

and Langer

, Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo , Proceedings of the National Academy of Sciences 103(16) (2006), 6315–6320.

110.

McNamara

J.O.

Andrechek

E.R.

Wang

Viles

K.D.

Rempel

R.E.

Gilboa

Sullenger

B.A.

and Giangrande

P.H.

, Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras, Nature Biotechnology 24(8) (2006), 1005–1015.

111.

Tian

Ding

Yang

Shen

Zhu

J.S.

and Yang

C.J.

, A multifunctional nanomicelle for real-time targeted imaging and precise near-infrared cancer therapy, Angewandte Chemie 126(36) (2014), 9698–9703.

112.

Hua

Zhou

Yuan

and Liu

, Selective collection and detection of MCF-7 breast cancer cells using aptamer-functionalized magnetic beads and quantum dots based nano-bio-probes, Analytica Chimica Acta 788 (2013), 135–140.

113.

Niazi

J.H.

Verma

S.K.

Niazi

and Qureshi

, In vitro HER2 protein-induced affinity dissociation of carbon nanotube-wrapped anti-HER2 aptamers for HER2 protein detection, Analyst 140(1) (2015), 243–249.

114.

Eikrem

O.S.

Strauss

Beisland

Scherer

Landolt

Flatberg

Leh

Beisvag

Skogstrand

and Hjelle

, Development and confirmation of potential gene classifiers of human clear cell renal cell carcinoma using next-generation RNA sequencing, Scandinavian Journal of Urology 50(6) (2016), 452–462.

115.

Cerchia

and De Franciscis

, Targeting cancer cells with nucleic acid aptamers, Trends in Biotechnology 28(10) (2010), 517–525.

116.

Camorani

Crescenzi

Gramanzini

Fedele

Zannetti

and Cerchia

, Aptamer-mediated impairment of EGFR-integrin αvβ3 complex inhibits vasculogenic mimicry and growth of triple-negative breast cancers, Scientific Reports 7 (2017), 46659.

117.

Shigdar

Lin

Pastuovic

Wei

and Duan

, RNA aptamer against a cancer stem cell marker epithelial cell adhesion molecule, Cancer Science 102(5) (2011), 991–998.

118.

Shigdar

Qiao

Zhou

S.-F.

Xiang

Wang

Lim

L.Y.

Kong

and Duan

, RNA aptamers targeting cancer stem cell marker CD133, Cancer Letters 330(1) (2013), 84–95.

119.

Bayat

Taghdisi

S.M.

Rafatpanah

Abnous

and Ramezani

, In vitro selection of CD70 binding aptamer and its application in a biosensor design for sensitive detection of SKOV-3 ovarian cells, Talanta 194 (2019), 399–405.

120.

Almasi

Gargari

S.L.M.

Bitaraf

and Rasoulinejad

, Development of a single stranded DNA aptamer as a molecular probe for lncap cells using cell-selex, Avicenna Journal of Medical Biotechnology 8(3) (2016), 104.

121.

Daniels

D.A.

Chen

Hicke

B.J.

Swiderek

K.M.

and Gold

, A tenascin-C aptamer identified by tumor cell SELEX: systematic evolution of ligands by exponential enrichment, Proceedings of the National Academy of Sciences 100(26) (2003), 15416–15421.

122.

Alshaer

Hillaireau

Vergnaud

Ismail

and Fattal

, Functionalizing liposomes with anti-CD44 aptamer for selective targeting of cancer cells, Bioconjugate Chemistry 26(7) (2015), 1307–1313.

123.

Haghighi

F.H.

Binaymotlagh

Mirahmadi-Zare

S.Z.

and Hadadzadeh

, Aptamer/magnetic nanoparticles decorated with fluorescent gold nanoclusters for selective detection and collection of human promyelocytic leukemia (HL-60) cells from a mixture, Nanotechnology 31(2) (2019), 025605.

124.

Fafińska

Czech

Sitz

Ignatova

and Hahn

, DNA aptamers for the malignant transformation marker CD24, Nucleic Acid Therapeutics 28(6) (2018), 326–334.

125.

Mallikaratchy

Tang

Kwame

Meng

Shangguan

and Tan

, Aptamer directly evolved from live cells recognizes membrane bound immunoglobin heavy mu chain in Burkitt’s lymphoma cells, Molecular & Cellular Proteomics 6(12) (2007), 2230–2238.

126.

Soldevilla

M.M.

Villanueva

and Pastor

, Aptamers: a feasible technology in cancer immunotherapy, Journal of immunology research, 2016.

127.

Lupold

S.E.

Hicke

B.J.

Lin

and Coffey

D.S.

, Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen, Cancer Research 62(14) (2002), 4029–4033.

128.

Shieh

Y.-A.

Yang

S.-J.

Wei

M.-F.

and Shieh

M.-J.

, Aptamer-based tumor-targeted drug delivery for photodynamic therapy, ACS Nano 4(3) (2010), 1433–1442.

129.

Cao

Tong

Mishra

Wong

G.C.L.

Cheng

and Lu

, Reversible cell-specific drug delivery with aptamer-functionalized liposomes, Angewandte Chemie International Edition 48(35) (2009), 6494–6498.

130.

Song

Zhu

Zhang

Liu

Duan

and Yang

C.J.

, Selection of DNA aptamers against epithelial cell adhesion molecule for cancer cell imaging and circulating tumor cell capture, Analytical Chemistry 85(8) (2013), 4141–4149.

131.

Xiang

Shigdar

Qiao

Wang

Kouzani

A.Z.

Zhou

S.-F.

Kong

and Duan

, Nucleic acid aptamer-guided cancer therapeutics and diagnostics: the next generation of cancer medicine, Theranostics 5(1) (2015), 23.

132.

Ferreira

C.S.M.

Matthews

C.S.

and Missailidis

, DNA aptamers that bind to MUC1 tumour marker: design and characterization of MUC1-binding single-stranded DNA aptamers, Tumor Biology 27(6) (2006), 289–301.

133.

Zhu

Zheng

Song

Donovan

Zhang

Liu

and Tan

, Self-assembled, aptamer-tethered DNA nanotrains for targeted transport of molecular drugs in cancer theranostics, Proceedings of the National Academy of Sciences 110(20) (2013), 7998–8003.

134.

Zhu

Zhao

Chen

Zhang

and Tan

, Noncanonical self-assembly of multifunctional DNA nanoflowers for biomedical applications, Journal of the American Chemical Society 135(44) (2013), 16438–16445.

135.

Chen

Zheng

Baade

P.D.

Zhang

Zeng

Bray

Jemal

X.Q.

and He

, Cancer statistics in China, 2015, CA: A Cancer Journal for Clinicians 66(2) (2016), 115–132.

136.

Alix-Panabières

and Pantel

, Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy, Cancer Discovery 6(5) (2016), 479–491.

137.

Nagrath

Sequist

L.V.

Maheswaran

Bell

D.W.

Irimia

Ulkus

Smith

M.R.

Kwak

E.L.

Digumarthy

and Muzikansky

, Isolation of rare circulating tumour cells in cancer patients by microchip technology, Nature 450(7173) (2007), 1235–1239.

138.

Jacob

Sollier

and Jabado

, Circulating tumor cells: detection, molecular profiling and future prospects, Expert Review of Proteomics 4(6) (2007), 741–756.

139.

Zhang

and Zhang

, A chemiluminescence imaging array for the detection of cancer cells by dual-aptamer recognition and bio-bar-code nanoprobe-based rolling circle amplification, Chemical Communications 49(33) (2013), 3452–3454.

140.

Kashefi-Kheyrabadi

Mehrgardi

M.A.

Wiechec

Turner

A.P.F.

and Tiwari

, Ultrasensitive detection of human liver hepatocellular carcinoma cells using a label-free aptasensor, Analytical Chemistry 86(10) (2014), 4956–4960.

141.

Zeng

Tung

C.-H.

and Zu

, A cancer cell-activatable aptamer-reporter system for one-step assay of circulating tumor cells, Molecular Therapy-Nucleic Acids 3 (2014), e184.

142.

Wang

Fan

Liu

and Wang

, Highly sensitive and specific colorimetric detection of cancer cells via dual-aptamer target binding strategy, Biosensors and Bioelectronics 73 (2015), 1–6.

143.

Sheng

Chen

Tan

and Fan

Z.H.

, Multivalent DNA nanospheres for enhanced capture of cancer cells in microfluidic devices, Acs Nano 7(8) (2013), 7067–7076.

144.

Massoud

T.F.

Paulmurugan

and Gambhir

S.S.

, Molecular imaging of homodimeric protein-protein interactions in living subjects, The FASEB Journal 18(10) (2004), 1105–1107.

145.

Zhong

Zhang

and Zhang

, High-intensity fluorescence imaging and sensitive electrochemical detection of cancer cells by using an extracellular supramolecular reticular DNA-quantum dot sheath, Chemistry – A European Journal 17(30) (2011), 8388–8394.

146.

Rockey

W.M.

Huang

Kloepping

K.C.

Baumhover

N.J.

Giangrande

P.H.

and Schultz

M.K.

, Synthesis and radiolabeling of chelator-RNA aptamer bioconjugates with copper-64 for targeted molecular imaging, Bioorganic & Medicinal Chemistry 19(13) (2011), 4080–4090.

147.

M.K.

Kim

Lee

I.H.

J.S.

Jeong

Y.Y.

and Jon

, Image-guided prostate cancer therapy using aptamer-functionalized thermally cross-linked superparamagnetic iron oxide nanoparticles, Small 7(15) (2011), 2241–2249.

148.

Zeng

Parekh

Shi

Z.-Z.

Tung

C.-H.

and Zu

, Specific and sensitive tumor imaging using biostable oligonucleotide aptamer probes, Theranostics 4(9) (2014), 945.

149.

Zhao

Bai

Yang

Liu

Champanhac

Teng

I.T.

and Ye

, DNA aptamer selected against pancreatic ductal adenocarcinoma for in vivo imaging and clinical tissue recognition, Theranostics 5(9) (2015), 985.

150.

Gao

Shen

Liu

and Xu

, A dual functional fluorescent probe for glioma imaging mediated by blood-brain barrier penetration and glioma cell targeting, Biochemical and Biophysical Research Communications 449(1) (2014), 44–48.

151.

Kim

Yang

Hwang

Choi

Kim

H.-O.

Jang

Lee

J.H.

Ryu

S.-H.

Suh

J.-S.

and Huh

Y.-M.

, Aptamer-modified magnetic nanoprobe for molecular MR imaging of VEGFR2 on angiogenic vasculature, Nanoscale Research Letters 8(1) (2013), 1–10.

152.

Heo

Lee

Hwang

Kim

Park

Lee

Y.H.

Huh

Y.-M.

Haam

and Cheong

J.-H.

, Maleimidyl magnetic nanoplatform for facile molecular MRI, Nanotechnology 25(27) (2014), 275102.

153.

Zeng

Zhang

Zhao

Sheehan

A.M.

Tung

C.-H.

Chang

C.-C.

and Zu

, Using oligonucleotide aptamer probes for immunostaining of formalin-fixed and paraffin-embedded tissues, Modern Pathology 23(12) (2010), 1553–1558.

154.

Jin

Zhu

Hao

Liu

Shi

Fan

and Yang

C.J.

, Evolution of DNA aptamers through in vitro metastatic-cell-based systematic evolution of ligands by exponential enrichment for metastatic cancer recognition and imaging, Analytical Chemistry 87(9) (2015), 4941–4948.

155.

Reinemann

and Strehlitz

, Aptamer-modified nanoparticles and their use in cancer diagnostics and treatment, Swiss Medical Weekly 144(0102) (2014).

156.

Zhang

Ali

M.M.

Eckert

M.A.

Kang

D.-K.

Chen

Y.Y.

Sender

L.S.

Fruman

D.A.

and Zhao

, A polyvalent aptamer system for targeted drug delivery, Biomaterials 34(37) (2013), 9728–9735.

Radiomics,aptamers and nanobodies: New insights in cancer diagnostics and imaging

Abstract

Keywords

1. Introduction

2. Radiomics in tumor diagnosis and prognosis

5. Molecular imaging of cancer using nanobodies

Table 1 List of nanobody probes used in cancer imaging

7. Conclusion

Footnotes

Acknowledgments

Conflict of interest

Funding

References

Table 1
List of nanobody probes used in cancer imaging